

08-04-2005

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) Tab settings



U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

103055562

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

08-10-80

1. Name of conveying party(ies):

SERENEX, INC.

- Individual(s) Association General Partnership Limited Partnership Corporation-State Other

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment Merger Security Agreement Change of Name Other

Execution Date: 7/18/05

2. Name and address of receiving party(ies)

Name: Venture Lending & Leasing IV, Inc.

Internal

Address:

Street Address: 2010 North First Street

City: San Jose State: CA Zip: 95131

- Individual(s) citizenship Association General Partnership Limited Partnership Corporation-State Maryland Other

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No (Designations must be a separate document from assignment) Additional name(s) & address(es) attached? Yes No

4. Application number(s) or registration number(s):

A. Trademark Application No.(s) 78/534,265

B. Trademark Registration No.(s) 2,870,062;

2,870,061;

Additional number(s) attached Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Russell D. Pollock, Esq.

Internal Address:

Street Address: Greene Radovsky Maloney & Share LLP Four Embarcadero Center, Suite 4000

City: San Francisco State: CA Zip: 94111

6. Total number of applications and registrations involved:

3

7. Total fee (37 CFR 3.41) \$ 90.00

- Enclosed Authorized to be charged to deposit account

8. Deposit account number:

DO NOT USE THIS SPACE

9. Signature.

Jeffrey T. Klugman

Name of Person Signing

Handwritten signature

Signature

7/28/05

Date

Total number of pages including cover sheet, attachments, and document: 16

Mail documents to be recorded with required cover sheet information to: Commissioner of Patent & Trademarks, Box Assignments Washington, D.C. 20231

08/03/2005 ECDOPER 00000101 78534265

01 FC:8521 02 FC:8522

40.00 OP 50.00 OP

TRADEMARK REEL: 003200 FRAME: 0786

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of July 18, 2005, by and between SERENEX, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING IV, INC., a Maryland corporation ("Secured Party").

RECITALS

A. Pursuant to a Loan and Security Agreement of even date herewith (the "Loan Agreement") between Grantor, as borrower, and Secured Party, as lender, Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest and mortgage to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor is now the sole owner of the Collateral, except for non-exclusive licenses granted by Grantor to its customers in the ordinary course of business;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for non-exclusive licenses granted by Grantor in the ordinary course of business or as set forth in this Agreement;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(d) **Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal quarter, a report signed by Grantor, in form reasonably acceptable to Secured Party, listing any applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks and the status of any outstanding applications or registrations. Grantor shall promptly advise Secured Party of any material change in the composition of the Collateral, including but not limited to any subsequent ownership right of the Grantor in or to any Trademark, Patent or Copyright not specified in this Agreement;**

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Secured Party in writing of material infringements detected and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public without the written consent of Secured Party, which consent shall not be unreasonably withheld;

(f) Grantor shall apply for registration on an expedited basis (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral. Grantor shall give Secured Party notice of all such applications or registrations; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts.

3. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, this Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law, and (iii) after the occurrence of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor breaches any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur

of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

GRANTOR:

Address of Grantor:

323 Foster Street
Durham, NC 27701
Attn: Chief Financial Officer

SERENEX, INC.

By: Richard Kent
Name: RICHARD KENT
Its: CEO

SECURED PARTY:

Address of Secured Party:

2010 North First Street, Suite 310
San Jose, CA 95131
Attn: President

VENTURE LENDING & LEASING IV, INC.

By: _____
Name: _____
Its: _____

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

GRANTOR:

Address of Grantor:

SERENEX, INC.

323 Foster Street
Durham, NC 27701
Attn: Chief Financial Officer

By: _____

Name: _____


Its: _____

SECURED PARTY:

Address of Secured Party:

VENTURE LENDING & LEASING IV, INC.

2010 North First Street, Suite 310
San Jose, CA 95131
Attn: President

By:  _____

Name: Ronald W. Swenson

Its: Chief Executive Officer

EXHIBITS A, B AND C TO BE COMPLETED BY GRANTOR

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

NONE

SERENEX PATENTS AND PATENT APPLICATIONS

Type	Title	Inventor	Application No./Patent No.	Filing Date	Status	Licensed	Assigned
UTILITY	Gamma Linked ATP Sepharose	Haystead	5,536,822	3/9/1994	Granted 7/16/96	Yes	UVA
PCT	Affinity Displacement Avidity Effect Protein Resolution Methods	Haystead	PCT/US2004/041673	12/10/2004	Pending	No	In Process
US UTILITY	Alkyl-Linked Nucleotide Compositions	Hardeman et al.	10/762,078	1/21/2004	Pending	No	In Process
PCT	Alkyl-linked Nucleotide Compositions	Hardeman et al.	PCT/US2004/001745	1/22/2004	Pending	No	Serenex
PCT	Folate Antagonists Having Improved Selectivity	Partridge	PCT/US2004/035719	10/28/2004	Pending	No	In Process
US UTILITY	Integrated Protein Affinity Capture Centrifugation Device	Haystead and Young	10/022,931 6,716,395	12/18/2001	Granted 4/6/04	No	Serenex
AU	Integrated Protein Affinity Capture Centrifugation Device	Haystead and Young	2002364063	12/17/2002	Pending	No	Serenex
CAN	Integrated Protein Affinity Capture Centrifugation Device	Haystead and Young	2,470,799	12/17/2002	Pending	No	Serenex
EPC	Integrated Protein Affinity Capture Centrifugation Device	Haystead and Young	2798530.8	12/17/2002	Pending	No	Serenex
PCT	Methods of Improving Therapy for HIV Infection	Kent Haystead Wadkins	PCT/US2004/029892	9/10/2004	Pending	No	Serenex
US UTILITY	Proteome Mining	Haystead	09/958,787	1/16/2002	MONITORING ONLY--Prosecution by Schwegman, Lundbert, Woessner & Kluth, PA of Minneapolis	Yes UVA	UV UVPF
AU	Proteome Mining	Haystead	42322/00	4/12/2000	Granted 10/21/2004	Yes UVA	N/A

Exhibit "B"

SERENEX PATENTS AND PATENT APPLICATIONS

Type	Title	Inventor	Application No./Patent No.	Filing Date	Status	Licensed	Assigned
AU DIVISIONAL	Proteome Mining	Haystead	2004218671	4/12/2000	MONITORING ONLY--Prosecution by Schwegman, Lundbert, Woessner & Kluth, PA of Minneapolis	Yes UVA	N/A
JP	Proteome Mining	Haystead	2000-612748	4/12/2000	MONITORING ONLY--Prosecution by Schwegman, Lundbert, Woessner & Kluth, PA of Minneapolis	Yes UVA	N/A
CA	Proteome Mining	Haystead	2,369,868	4/12/2000	MONITORING ONLY--Prosecution by Schwegman, Lundbert, Woessner & Kluth, PA of Minneapolis	Yes UVA	N/A
EP	Proteome Mining	Haystead	922084.9	4/12/2000	MONITORING ONLY--Prosecution by Schwegman, Lundbert, Woessner & Kluth, PA of Minneapolis	Yes UVA	N/A
US UTILITY	Quinone Reductase 2 and Aldehyde Dehydrogenase as Therapeutic Targets	Haystead	10/243,947	9/16/2002	Takeover File-- MONITORING ONLY--Prosecution by Nixon & Vanderhye P.C., Arlington, VA.	Yes Duke	N/A

SERENEX PATENTS AND PATENT APPLICATIONS

Type	Title	Inventor	Application No./Patent No.	Filing Date	Status	Licensed	Assigned
AU	Quinone Reductase 2 and Aldehyde Dehydrogenase as Therapeutic Targets	Haystead	20023336528	9/16/2002	Takeover File-- MONITORING ONLY--Prosecution by Nixon & Vanderhye P.C., Arlington, VA. (File No. 1579-894)	Yes Duke	N/A
CA	Quinone Reductase 2 and Aldehyde Dehydrogenase as Therapeutic Targets	Haystead	2,460,317	9/16/2002	Takeover File-- MONITORING ONLY--Prosecution by Nixon & Vanderhye P.C., Arlington, VA. (File No. 1579-895)	Yes Duke	N/A
EP	Quinone Reductase 2 and Aldehyde Dehydrogenase as Therapeutic Targets	Haystead	2773382.3	9/16/2002	Takeover File-- MONITORING ONLY--Prosecution by Nixon & Vanderhye P.C., Arlington, VA. (File No. 1579-896)	Yes Duke	N/A
PROVISIONAL	Methotrexate Derivatives Useful for Treating Cancer and Arthritis	Hanson and Barta	60/589,696	7/21/2004	Pending		Serenex
PCT	Methotrexate Derivatives Useful for Treating Cancer and Arthritis				Docketed - Unfiled		

SERENEX PATENTS AND PATENT APPLICATIONS

Type	Title	Inventor	Application No./Patent No.	Filing Date	Status	Licensed	Assigned
PROVISIONAL	Substituted Quinolone and Quinazoline Inhibitors of Quinone Reductase 2	Ware Cosselmon Allen Wadkins	60/611,471	9/20/2004	Pending		
DESIGN	Gel Band Picking Head	Cosselmon Allen Fadden Partridge	29/223,501	2/15/2005	Pending		Serenex
DESIGN	Gel Box for an Auto Sample Feed Gel System		29/223,479	2/15/2005	Pending		Serenex

U.S. Trademark Case Summary

SERENEX, INC.

June 14, 2005

Filing Date	Case Status	Application Serial Number/ Type	Reg. No.	Mark	Summary Detailed Status	Goods/Services
12/6/2001	Registered 8/3/2004	I	76346149 2870062	SERENEX	8/3/2010 - File §§15 Affidavits	Drug discovery services; pharmaceutical research services; pre-clinical screening, and clinical research and evaluation services; proteomics and pharmacology research services; development of human disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening; compilation of databases for use in pharmaceutical research; consultancy, information and advisory services for all the aforesaid services, all of the foregoing services provided exclusively to researchers engaged in drug discovery and development , in International Class 042
12/6/2001	Registered 8/3/2004	I	76345887 2870061	SERENEX (stylized) [corporate logo]	8/3/2010 - File §§15 Affidavits	Drug discovery services; pharmaceutical research services; pre-clinical screening, and clinical research and evaluation services; proteomics and pharmacology research services; development of human disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening; compilation of databases for use in pharmaceutical research; consultancy, information and advisory services for all the aforesaid services, all of the foregoing services provided exclusively to researchers engaged in drug discovery and development, in International Class 042
12/17/2004	Pending	I	78534265	(misc. design) [new logo design]		Drug discovery services; pharmaceutical research services; pre-clinical screening, and clinical research and evaluation services; proteomics and pharmacology research services; development of human disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening; compilation of databases for use in pharmaceutical research; consultancy, information and advisory services for all the aforesaid services, all of the foregoing services provided exclusively to researchers engaged in drug discovery and development., in International Class 042
2/14/2002	Abandoned 9/1/2004	I	76371010	FPF	9/1/2004 - Abandoned	
12/6/2001	Abandoned 12/31/2003	I	76346142	FUNCTIONAL PROTEOME FRACTIONATION	11/10/2003 - Abandoned.	

*Bolded items indicate action due in the near future.

H+M: 163872.01

Page 1

TRADEMARK

REEL: 003200 FRAME: 0798

U.S. Trademark Case Summary
 SERENEX, INC.
 June 14, 2005

Filing Date	Case Status	Type	Application		Mark	Summary Detailed Status	Goods/Services
			Serial Number/Reg. No.	Reg. No.			
Filing Date: 12/6/2001	Abandoned 3/20/2005	I	76346144	76346144	PROTEOME MINING	3/20/2005 - Abandoned.	
Filing Date: 12/6/2001	Abandoned 9/9/2003	I	76346131	76346131	RATIONALIZING PROTEOMICS	9/9/2003 - Abandoned	

*Bolded items indicate action due in the near future.

Foreign Trademark(s)

Country/ Filing Date	Status Summary	Application Serial No. Registration No.	Application Mark	Summary Detailed Status
Australia 6/6/2002	Registered	915546	SERENEX (and design)	6/6/2012 - Last date to renew Registration.
Australia 6/6/2002	Registered	915544	SERENEX	6/6/2012 - Last date to renew Registration.
Australia 6/5/2002	Halted	915547	RATIONALIZING PROTEOMICS	5/19/2003 - Halted at client's request.
Australia 6/5/2002	Halted	915548	FUNCTIONAL PROTEOME FRACTIONATION	9/10/2003 - Halted at client's request.
Australia 6/5/2002	Halted	915549	PROTEOME MINING	9/10/2003 - Halted at client's request.
Australia 6/6/2002	Halted	915550	FPF	9/11/2003 - Halted at client's request.
Canada 5/31/2002	Pending	1,141,989	SERENEX	12/3/2005 PA instructed to file Extension of Dec of Use
Canada 5/31/2002	Halted	1,141,992	SERENEX (AND DESIGN)	3/8/2005 - Halted at client's request.
Canada 6/5/2002	Halted	1,142,312	RATIONALIZING PROTEOMICS	5/19/2003 - Halted at client's request.
Canada 6/5/2002	Halted	1,142,311	FUNCTIONAL PROTEOME FRACTIONATION	9/10/2003 - Halted at client's request.
Canada 6/5/2002	Halted	1,142,306	PROTEOME MINING	9/10/2003 - Halted at client's request.
Canada 6/5/2002	Halted	1,142,313	FPF	9/12/2003 - Halted at client's request.
OHIM (OAMI) 6/6/2002	Registered	002726321	SERENEX (Figurative Mark)	6/6/2012 - File renewal with OHIM
OHIM (OAMI) 6/6/2002	Registered	002726370	SERENEX	6/6/2012 - Last date to renew Registration.
OHIM (OAMI) 6/6/2002	Halted	002726479	RATIONALIZING PROTEOMICS	5/19/2003 - Halted at client's request.

TRADEMARK

REEL: 003200 FRAME: 0800

*Bolded items indicate action due in the near future.

Foreign Trademark(s)

Country/ Filing Date	Status Summary	Application Serial No. Registration No.	Application Mark	Summary Detailed Status
OHIM (OAMI) 6/6/2002	Halted	002726339	FUNCTIONAL PROTEOME FRACTIONATION	9/10/2003 - Halted at client's request.
OHIM (OAMI) 6/6/2002	Halted	002726354	PROTEOME MINING	9/10/2003 - Halted at client's request.
OHIM (OAMI) 6/6/2002	Halted	002726438	FPF	9/12/2003 - Halted at client's request.

RECORDED: 08/01/2005

TRADEMARK
REEL: 003200 FRAME: 0801

*Bolted items indicate action due in the near future.